Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MS017
- Development stage
- Preclinical
- Lead developer
- Hangzhou Medimscience Biomedical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MS017 is a monoclonal antibody being developed by Medimscience for the treatment of solid tumors. It targets MT017, a proprietary macrophage-related protein involved in the regulation of the tumor microenvironment. By targeting this specific protein, MS017 is designed to modulate macrophage function to promote an anti-tumor immune response. The drug is currently in the IND-enabling phase of development, representing a novel approach to cancer immunotherapy by focusing on the myeloid compartment of the tumor microenvironment.
- Other names
- MT017 monoclonal antibodyMT-017 monoclonal antibodyMT 017 monoclonal antibody
02
Targets
MTNR1A (MT1)
Beyond the preview
Go deeper on MS017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MS017.